JPWO2020102142A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020102142A5 JPWO2020102142A5 JP2021525119A JP2021525119A JPWO2020102142A5 JP WO2020102142 A5 JPWO2020102142 A5 JP WO2020102142A5 JP 2021525119 A JP2021525119 A JP 2021525119A JP 2021525119 A JP2021525119 A JP 2021525119A JP WO2020102142 A5 JPWO2020102142 A5 JP WO2020102142A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleosides
- composition
- subscript
- modified oligonucleotide
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002777 nucleoside Substances 0.000 claims 37
- 125000003835 nucleoside group Chemical group 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 18
- 229920000272 Oligonucleotide Polymers 0.000 claims 15
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims 14
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims 14
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 9
- 206010064571 Gene mutation Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 206010018338 Glioma Diseases 0.000 claims 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 6
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 5
- HQULDBYHEHYKRS-UHFFFAOYSA-N 6-amino-1H-pyrimidin-2-one Chemical class NC1=CC=NC(O)=N1.NC=1C=CNC(=O)N=1 HQULDBYHEHYKRS-UHFFFAOYSA-N 0.000 claims 3
- 208000005017 Glioblastoma Diseases 0.000 claims 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 239000005547 deoxyribonucleotide Substances 0.000 claims 3
- 229960004964 temozolomide Drugs 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 206010002224 Anaplastic astrocytoma Diseases 0.000 claims 2
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims 2
- 210000000349 Chromosomes Anatomy 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000001169 fibrillary astrocytoma Diseases 0.000 claims 2
- 201000011626 grade III astrocytoma Diseases 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 201000010133 oligodendroglioma Diseases 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 238000002271 resection Methods 0.000 claims 2
- 230000004083 survival Effects 0.000 claims 2
- 108010005144 Bevacizumab Proteins 0.000 claims 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 1
- 101700024037 IDH1 Proteins 0.000 claims 1
- 102100004121 IDH1 Human genes 0.000 claims 1
- 101700030371 IDH2 Proteins 0.000 claims 1
- 102100002772 IDH2 Human genes 0.000 claims 1
- 101700066748 IDH3B Proteins 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical group ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 150000004713 phosphodiesters Chemical class 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760546P | 2018-11-13 | 2018-11-13 | |
| US62/760,546 | 2018-11-13 | ||
| PCT/US2019/060841 WO2020102142A1 (fr) | 2018-11-13 | 2019-11-12 | Composés de microarn et méthodes de modulation de l'activité du mir-10b |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506958A JP2022506958A (ja) | 2022-01-17 |
| JPWO2020102142A5 true JPWO2020102142A5 (fr) | 2022-10-03 |
Family
ID=68808539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525119A Pending JP2022506958A (ja) | 2018-11-13 | 2019-11-12 | Ｍｉｒ－１０ｂ活性を調節するためのマイクロｒｎａ化合物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220096517A1 (fr) |
| EP (1) | EP3880310A1 (fr) |
| JP (1) | JP2022506958A (fr) |
| KR (1) | KR20210091732A (fr) |
| CN (1) | CN112996568A (fr) |
| AU (1) | AU2019381681A1 (fr) |
| CA (1) | CA3117981A1 (fr) |
| MA (1) | MA54226A (fr) |
| TW (1) | TW202031268A (fr) |
| WO (1) | WO2020102142A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110290794A (zh) | 2016-11-01 | 2019-09-27 | 纽约州州立大学研究基金会 | 5-卤代尿嘧啶修饰的微rna及其在癌症治疗中的用途 |
| US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007303205A1 (en) | 2006-10-03 | 2008-04-10 | Tekmira Pharmaceuticals Corporation | Lipid containing formulations |
| AU2009283906A1 (en) * | 2008-08-19 | 2010-02-25 | Maine Institute For Human Genetics And Health | Micro RNA and Neurofibromatosis Type 1 in diagnosis and therapy |
| ES2555057T3 (es) * | 2009-06-12 | 2015-12-28 | Roche Innovation Center Copenhagen A/S | Nuevos potentes compuestos antisentido anti-ApoB |
| US9364495B2 (en) * | 2009-10-20 | 2016-06-14 | Roche Innovation Center Copenhagen A/S | Oral delivery of therapeutically effective LNA oligonucleotides |
| US9322016B2 (en) * | 2011-09-07 | 2016-04-26 | 3-D Matrix Ltd. | MicroRNA-based methods and assays for osteosarcoma |
| JP6322189B2 (ja) * | 2012-04-25 | 2018-05-09 | レグルス セラピューティクス インコーポレイテッド | Ｍｉｒ−２１活性を調節するためのマイクロｒｎａ化合物及び方法 |
| MA46999A (fr) * | 2016-12-05 | 2019-10-09 | Regulus Therapeutics Inc | Oligonucléotides modifiés pour traiter la polykystose rénale |
-
2019
- 2019-11-12 WO PCT/US2019/060841 patent/WO2020102142A1/fr unknown
- 2019-11-12 JP JP2021525119A patent/JP2022506958A/ja active Pending
- 2019-11-12 TW TW108140918A patent/TW202031268A/zh unknown
- 2019-11-12 CN CN201980074354.1A patent/CN112996568A/zh active Pending
- 2019-11-12 EP EP19817004.5A patent/EP3880310A1/fr not_active Withdrawn
- 2019-11-12 US US17/290,298 patent/US20220096517A1/en active Pending
- 2019-11-12 KR KR1020217016717A patent/KR20210091732A/ko not_active Application Discontinuation
- 2019-11-12 CA CA3117981A patent/CA3117981A1/fr active Pending
- 2019-11-12 AU AU2019381681A patent/AU2019381681A1/en active Pending
- 2019-11-12 MA MA054226A patent/MA54226A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Karras et al. | Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma | |
| Nemunaitis et al. | A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients | |
| Hotte et al. | An optimized clinical regimen for the oncolytic virus PV701 | |
| JP2022159552A (ja) | ｉＮＯＳ阻害組成物および乳がん治療薬としてのその使用 | |
| JP2009143930A (ja) | Ｃｓｆ−１インヒビターの使用 | |
| AU2015374385A1 (en) | Combination tumor immunotherapy | |
| US10379767B2 (en) | Methods of using OX40 ligand encoding polynucleotides | |
| JP6290316B2 (ja) | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 | |
| US11273170B2 (en) | Methods of treating cancer | |
| KR101843985B1 (ko) | 암을 치료하기 위한 조성물과 방법 | |
| Nuno Moreira et al. | Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality | |
| JP2019517815A (ja) | 細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現 | |
| WO2009114459A2 (fr) | Régime thérapeutique antinéoplasique combiné comprenant la co-disruption de la voie parp et du complexe mre11/rad50/nbs1, et compositions utiles à cette fin | |
| RU2535993C2 (ru) | Молекула rnai, нацеливающая тимидилатсинтазу и ее применение | |
| Santhanam et al. | Potential of interferon-α in solid tumours: part 2 | |
| JPWO2020102142A5 (fr) | ||
| JP2009540857A (ja) | Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法 | |
| JP6574136B2 (ja) | Ｅｇｆｒの発現をサイレンシングするためのｄｎａザイム | |
| US20080274121A1 (en) | Inhibition of Angiogenesis by Mithramycin | |
| KR101993377B1 (ko) | Bcl2 유전자 및 bi-1 유전자의 발현을 동시에 억제하는 핵산 | |
| DK2613789T3 (en) | SDF-1-binding nucleic acids and their use in cancer treatment | |
| US20230151363A1 (en) | Modified short-interfering rna compositions and their use in the treatment of cancer | |
| US20240139345A1 (en) | Nucleic acid vectors and methods of use | |
| JP2023519580A (ja) | 治療抵抗性ｍｕｃ４＋癌を処置するための方法 | |
| US20110268763A1 (en) | Polynucleotides that stimulate neutrophils |